MedTrace Logo

Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle

NCT04141930 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 481

Last updated 2021-08-05

Study results available
· View outcomes & findings →

Summary

This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset.

Conditions

Interventions

DRUG

Baloxavir Marboxil

Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset

Sponsors & Collaborators

Principal Investigators

  • Helen Y Chu, MD, MPH · University of Washington

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2020-04-01
Completion
2020-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04141930 on ClinicalTrials.gov